Q3 Earnings Forecast for Opus Genetics Issued By Wedbush

Opus Genetics, Inc. (NASDAQ:IRD) – Equities research analysts at Wedbush issued their Q3 2025 earnings per share estimates for shares of Opus Genetics in a report issued on Wednesday, October 29th. Wedbush analyst Y. Zhong expects that the company will post earnings of ($0.14) per share for the quarter. Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. Wedbush also issued estimates for Opus Genetics’ Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.64) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.33) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at $0.02 EPS.

A number of other equities analysts have also recently commented on the company. Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Chardan Capital initiated coverage on Opus Genetics in a report on Thursday, October 16th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Opus Genetics currently has an average rating of “Moderate Buy” and an average price target of $7.80.

Opus Genetics Price Performance

Shares of Opus Genetics stock opened at $2.30 on Friday. The stock has a market cap of $137.79 million, a price-to-earnings ratio of -1.20 and a beta of 0.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.90 and a current ratio of 1.90. The stock has a 50 day moving average price of $1.68 and a 200-day moving average price of $1.24. Opus Genetics has a one year low of $0.65 and a one year high of $2.30.

Opus Genetics (NASDAQ:IRD) last announced its earnings results on Friday, May 7th. The company reported ($0.47) EPS for the quarter. Opus Genetics had a negative return on equity of 384.33% and a negative net margin of 377.89%.

Hedge Funds Weigh In On Opus Genetics

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Opus Genetics during the 1st quarter valued at $26,000. Apollon Wealth Management LLC purchased a new position in Opus Genetics during the 1st quarter valued at $28,000. Comerica Bank purchased a new position in Opus Genetics during the 1st quarter valued at $29,000. Opaleye Management Inc. raised its position in Opus Genetics by 3.8% during the 2nd quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company’s stock valued at $1,149,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Kestra Private Wealth Services LLC bought a new stake in Opus Genetics during the 1st quarter valued at $47,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.